BRKRP · Bruker Corp · Investor Relations

Dimension IconIR to Support Critical Materials Characterization for Next-Generation Semiconductor Devices Bruker Corporation (Nasdaq: BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges facing the semiconductor industry as device architectures continue to shrink and systems become increasingly more complex. As the largest supplier of nanoscale infrared (nanoIR) spectroscopy technology to the semiconductor industry, Bruker is expanding the use of AFM-IR beyond its established role in nanoscale contamination analysis into research areas that underpin next-generation semiconductor technologies. These include EUV photoresist patterning and development, advanced materials for transistor scaling, and site-selective surface functionalization at the nanoscale for emerging sensing and functional device applications. Bruker’s Dimension IconIR system at imec with (left to right) Hartmut Stadler (Bruker), Dowon Kim

Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience. Thierry Bernard Frank H. Laukien, the Chairman, President and CEO of Bruker Corporation, stated: “Bruker is delighted that Thierry is joining our Board. I have admired his successful track record, astute strategic initiatives, and outstanding execution for many years, and I am convinced that Thierry will be an excellent addition to our Board of Directors as we further develop our leadership position in life-science research, biopharma, and diagnostic solutions in the post-genomic era, and aim for profitable growth and rapid margin expansion to enhance stakeholder value.” Mr. Bernard currently serves as Chief Executive Officer of QIAGEN N.V. He joined QIAGEN in 2015 to lead

US PTAB Revokes Sole Independent and Other Central Claims of U.S. Patent 11,435,360 PreOmics GmbH and Biognosys AG today announced a favorable outcome in an inter partes review (IPR) proceeding IPR2024‑01473 before the U.S. Patent Trial and Appeal Board (PTAB). The PTAB has revoked the central claims of U.S. Patent No. 11,435,360, which is owned by The Brigham and Women’s Hospital, and exclusively licensed to Seer, Inc. The USPTO struck down the sole independent claim of the ‘360 patent, among other claims. The PTAB specifically invalidated Claim 1, which attempted to cover workflows using multiple nanoparticle types to form biomolecule coronas and detect proteins across a wide dynamic range. “This outcome confirms what we have consistently believed from the outset: the fundamental concepts at issue were already known in the scientific literature,” said Dr. Oliver Rinner, co-founder and managing director of Biognosys AG. “We welcome the PTAB’s thorough evaluation and we are very

The new platform delivers unmatched quantitation, robustness, and throughput to support clinical translation of spatial proteomics assays Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical applications. As spatial proteomics moves from discovery to translational research and to diagnostic development, researchers face increasing demands for assay reproducibility, standardization, quantitative confidence, and throughput across large clinical cohorts. CellScape XR incorporates advances in optics, fluidics, and protocols to specifically meet these needs, combining highly